Clik here to view.
Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent...
DUBLIN Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced the 12-month results of the 14 Presbia Flexivue Microlens™ surgeries performed on...
View ArticleClik here to view.
SalutarisMD to Introduce its New Generation Medical Device for wet AMD...
COPENHAGEN, Denmark Today, Salutaris Medical Devices, Inc. (SalutarisMD®) announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the Company will...
View ArticleClik here to view.
Clik here to view.
Clinigen Launches Japanese Business to Strengthen Asian Presence
TOKYO Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The...
View ArticleClik here to view.
Acucela Issues Notice of Resolutions of the Annual Meeting of Shareholders
SEATTLE Acucela Inc. (Tokyo: 4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticleClik here to view.
Acucela Issues Notice of Listing Approval of Kubota Pharmaceutical Holdings
SEATTLE Acucela Inc. (Tokyo:4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticleClik here to view.
Hoya Reports Second Quarter Results
TOKYO Hoya Corporation (TOKYO: 7741) today announced financial results for the second quarter ended September 30, 2016. During the quarter, revenue of the HOYA Group decreased 11.8% year on year, to...
View ArticleClik here to view.
新的里程碑研究显示，成人糖尿病患者存在不必要的失明风险
英格兰纽伯里 (美国商业资讯) — 对失明的恐惧是对糖尿病其他常见并发症（包括心血管疾病和卒中）恐惧的两倍之多，尽管如此，在受访的糖尿病患者中，有四分之一的病人并没有与他们的医疗保健专业人员讨论眼科并发症，许多人在视力问题已发生时才去就诊。1 今天发布的DR...
View ArticleClik here to view.
画期的な新調査で成人糖尿病患者は不必要な失明リスクを持つことが判明
英ニューベリー （ビジネスワイヤ） — 失明は糖尿病の他の合併症（心血管疾患および脳卒中を含む）の脅威より2倍多いにもかかわらず、調査を受けた糖尿病患者の4分の1は眼合併症について担当の医療専門家と話し合っておらず、多くの患者は視覚障害が生じてから診察を受けています1。これらの問題は、本日発表されたDR Barometer...
View ArticleClik here to view.
Listing of Kubota Pharmaceutical Holdings Co., Ltd. and Forecast for Fiscal...
TOKYO Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) (the “Company”) hereby gives notice that the merger agreement regarding its proposed redomicile transaction became effective on December...
View ArticleClik here to view.
神経栄養性角膜炎：ドンペが提出したCenegermin点眼薬（Oxervate®）の市販承認申請をEMAが受理
ミラノ — （ビジネスワイヤ） — バイオ医薬品企業のドンペは、欧州医薬品庁（EMA）に提出した点眼薬Oxervate®の登録申請が受理されたと発表しました。Oxervate®は中等度および重度の神経栄養性角膜炎の成人患者を治療する医薬品です。...
View ArticleClik here to view.
Acucela Secures Option to Exclusively Acquire Novel Retinal Technology
SEATTLE Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) that specializes in identifying and...
View ArticleClik here to view.
サルタリス・メディカル・デバイシズが米国FDAからSMD-Sr90-DA小線源で510(k)認証を取得
米アリゾナ州ツーソン （ビジネスワイヤ） — サルタリス・メディカル・デバイシズ（SalutarisMD®）は、米国食品医薬品局（FDA）から当社のSMD-Sr90-DA™小線源で510(k)認証を取得しました。SMD-Sr90-DA™デバイスは上強膜小線源療法が適応となります。本デバイスはマニュアルの小線源アプリケーターシステムでの使用を意図しています。 このSmart News...
View ArticleClik here to view.
InFo 124M – 瑞士生产的用于白内障手术的延伸焦深人工晶体
瑞士纳沙泰尔 (美国商业资讯) — Swiss Advanced Vision公司(SAV-IOL SA – www.sav-iol.com)不断壮大其人工晶体(IOL)产品阵容，宣布上市一款新产品，该产品基于该公司于2016年1月首次上市的InFo系列。InFo晶体旨在白内障手术后替换晶状体，使患者恢复视力，免于佩戴眼镜，避免了不必要的视觉不良效应，并保全解像度。 Smart News...
View ArticleClik here to view.
ファインデックス、愛媛大工学部・京都大医学部との共同研究により新たな検査手法を用いた視野検査システムの開発に着手
東京 （ビジネスワイヤ） — 株式会社ファインデックス（東証一部：3649 本社：東京 代表取締役：相原輝夫、以下ファインデックス）は、国立大学法人愛媛大学（学長：大橋 裕一、以下愛媛大学）と「新規視覚特性計測法を用いた視野計測装置の研究開発」、および国立大学法人京都大学（総長：山極 壽一、以下京都大学）との「視機能評価プログラム医療機器開発研究」に着手いたしました。...
View ArticleClik here to view.
InFo 124M – スイス製の白内障手術用EDOF IOL
スイス・ヌーシャテル （ビジネスワイヤ） — Swiss Advanced Vision（SAV-IOL SA –...
View ArticleClik here to view.
Hoya Announces Third Quarter Financial Results
TOKYO Hoya Corporation (TOKYO:7741) today announced financial results for the third quarter ended December 31, 2016. During the quarter, revenues for the HOYA Group amounted to 122,594 million yen,...
View ArticleClik here to view.
US Medical Device Company Visioneering Technologies, Inc. to List On ASX –...
ALPHARETTA, Georgia Visioneering Technologies, Inc. (VTI), a US based medical device company, is pleased to announce the opening of its fully underwritten Initial Public Offering (IPO) to raise...
View ArticleClik here to view.
EFIL Center Is Attracting Overseas Patients to Its Exophthalmos Center, Korea
DAEGU, South Korea JCI(Joint Commission International)-accredited EFIL Plastic Surgery is drawing attention across the globe with its exophthalmos surgery. This Smart News Release features...
View ArticleClik here to view.
Medical Device Company Visioneering Technologies Successfully Raises $33.3...
ALPHARETTA, Ga. Visioneering Technologies, Inc. (VTI), a US-based medical device company engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day...
View Article